Corcept Therapeut…
USUSDCorcept Therapeutics Incorporated (US:CORT) — Biotechnology: Pharmaceutical Preparations. Брой борси, на които се търгуват акциите на компанията: 2. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За Компанията
- Уебсайт
- corcept.com
- Връзки с Инвеститорите
- ir.corcept.com/
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Централа
- Menlo Park, United States
- Изпълнителен Директор
- Joseph K. Belanoff
- Служители
- 730
- Основана
- 1998
- Акции в Обращение
- 108.1 млн към 2026-07-22
- Свободно Търгуеми Акции
- 96.47 млн
- Пазарна Капитализация
- 12.4 млрд USD
- Инсайдери
- 11.47%
- Институционални Инвеститори
- 76.86%
- Отрасъл (SIC)
- Pharmaceutical Preparations
- ISIN
- US2183521028
- LEI
- 529900EO9LUTFMZ7FF90
- P/E
- 269
- FCF
- 107 млн USD
- Дълг
- 0 USDнетни парични средства
- Печалби и FCF — за 12-те месеца до 30.06.2026 (последният доклад на компанията).
Описание
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Най-Големи Притежатели
| Притежател | Дял | Акции | Дата на Доклада |
|---|---|---|---|
| Blackrock Inc. | 11.5% | 12.43 млн | 2026-06-30 |
| Ingalls & Snyder LLC | 7.34% | 7.93 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 5.39% | 5.82 млн | 2026-08-31 |
| BAKER GEORGE LEONARD JR.… | ≈5.14% | 5.55 млн | 2026-03-17 |
| Renaissance Technologies… | 4.87% | 5.26 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.67% | 5.04 млн | 2026-06-30 |
| Vanguard Capital Managem… | 3.86% | 4.17 млн | 2026-06-30 |
| Parallel Advisors, LLC | 3.67% | 3.96 млн | 2026-06-30 |
| FMR, LLC | 3.09% | 3.34 млн | 2026-06-30 |
| State Street Corporation | 3.03% | 3.28 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.68% | 2.89 млн | 2026-06-30 |
| AQR Capital Management,… | 2.39% | 2.58 млн | 2026-06-30 |
| Geode Capital Management… | 2.34% | 2.53 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.94% | 2.09 млн | 2026-06-30 |
| Fidelity Contrafund | 1.35% | 1.46 млн | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.12% | 1.21 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.01% | 1.1 млн | 2026-06-30 |
| First TRT Exch-Trd Fd.-F… | 0.91% | 985 377 | 2026-08-31 |
| iShares Trust-iShares S&… | 0.84% | 903 895 | 2026-08-31 |
| SPDR SERIES TRUST-State… | 0.83% | 898 881 | 2026-08-31 |
| VANGUARD TAX-MANAGED FUN… | 0.57% | 615 785 | 2026-06-30 |
| HUNT HAZEL (Officer) | ≈0.24% | 255 437 | 2026-02-09 |
| MADUCK SEAN (Officer) | ≈0.11% | 119 655 | 2026-09-01 |
| ROBB GARY CHARLES (Offic… | ≈0.07% | 74 343 | 2026-09-24 |
| MOKARI ATABAK (Chief Fin… | ≈0.02% | 16 304 | 2026-09-01 |
| LYON JOSEPH DOUGLAS (Chi… | ≈0.01% | 5 683 | 2026-09-14 |
| GUYER WILLIAM (Officer) | ≈0% | 4 313 | 2026-09-01 |
| BELANOFF JOSEPH K (Chief… | — | — | 2026-06-01 |
| MAHONEY DAVID L (Directo… | — | — | 2026-08-18 |
| WILSON JAMES N (Director… | — | — | 2026-09-15 |
